The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders.

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

The anesthetic ketamine is being hailed as a breakthrough therapy for people with post-traumatic stress disorder (PTSD), treatment-resistant depression and other mood disorders. But the drug does have ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Neumora Therapeutics Inc. concealed critical issues with its flagship clinical depression drug’s Phase 2 trial, contributing ...

Green, who was coming off a year-long suspension in 2010 after testing positive for marijuana, tested positive for marijuana ...

Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

Strahan is far from alone. He’s one of a growing number of people turning to psychedelics to treat mental health issues such ...